Biotech and Pharma Industry News | BioPharma Dive
BioPharma Dive provides news and analysis for biotech and biopharmaceutical executives. We cover topics like clinical trials, drug discovery and development, pharma marketing, FDA approvals and regulations, and more.
Drugmakers are racing to find the next Wegovy. These obesity …
Oct 10, 2024 · Within the pharmaceutical industry, a multibillion-dollar race is underway to top Novo Nordisk’s and Eli Lilly’s in-demand obesity drugs. Dozens of companies, large and small, have set out to test experimental medicines they claim could be more potent, convenient or have fewer side effects than Novo’s Wegovy and Lilly’s Zepbound.
The top biopharma conferences in 2025 | BioPharma Dive
Oct 1, 2024 · American Association of Cancer Research Annual Meeting. April 25 - 30, 2025 Chicago. While the American Society of Clinical Oncology’s meeting often gets billed as the field’s largest conference, AACR has become an equally major gathering for cancer research, particularly earlier-stage findings on new drug mechanisms of action or treatment modalities.
Biotech startups are built on venture capital. Track funding rounds ...
Nov 21, 2024 · With the funding of two startups this week, OrbiMed has passed Alexandria Venture Investments to become the third most active biotech investor since 2022, according to BioPharma Dive data.
The biopharma industry outlook on 2024: Guarded optimism for a …
Jan 16, 2024 · Guarded optimism seems to be the mood of the biopharmaceutical industry to start 2024.. Last year brought a stock market slide and layoffs for more than 150 drug companies. Financial and regulatory headwinds, like the March collapse of Silicon Valley Bank and a more strident Federal Trade Commission, further weighed on the sector.. There are now some signs of a turnaround, from a rebounding ...
Biotech M&A has plateaued. Track the deals that are happening …
Dec 16, 2024 · Methodology. For this database, BioPharma Dive looked only at companies developing human medicines. The mergers and acquisitions included in the database are limited by certain criteria, namely that they must be for an entire company — not for product licensings, options to acquire or for partial equity stakes.
Revolution Medicines firms up Phase 3 trial plans with latest …
Jul 15, 2024 · Revolution Medicines firms up Phase 3 trial plans with latest cancer drug data Updated results show the biotech’s therapy shrank pancreatic tumors in 20% to 25% of study participants, but with high rates of side effects like rash and nausea.
Biotech IPOs are the industry’s lifeblood. Track how they’re …
Dec 3, 2024 · Initial public offerings make the biotechnology industry tick. Stock listings give young companies the funding they need to develop their drugs, and their venture backers an opportunity to earn a return. For much of the past decade, biotechs found Wall Street receptive to their pitches. Public ...
Drug patents protect pharma profits. Track when they’ll expire.
May 8, 2024 · Patents reward drugmakers for their inventions and, effectively, the large sums of money they invest in research and development. The legal monopoly that patents provide keeps generic copies at bay for many years, even decades, and allows pharmaceutical companies to set higher prices than they otherwise could.
FDA, after delay, clears Regeneron and Sanofi drug for COPD
Sep 27, 2024 · The clearance is expected to further boost sales of Dupixent, which is a key source of revenue for both Sanofi and Regeneron. Since first reaching the U.S. market in 2017 as a treatment for eczema, Dupixent has now been cleared for six other diseases.